BioXcel Therapeutics (BTAI) CFO exercises RSUs and lifts direct holdings to 6,645 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BioXcel Therapeutics, Inc. Chief Financial Officer Richard Steinhart increased his equity stake through routine RSU vesting and exercises. On March 14 and 15, 2026, he exercised Restricted Stock Units that delivered a total of 68 shares of Common Stock at an exercise price of $0.00 per share. Following these transactions, he directly holds 6,645 shares of Common Stock. The filings also show remaining unexercised RSU balances of 247 units from a March 15, 2023 grant and 97 units from a March 14, 2022 grant, each RSU representing the right to receive one share of Common Stock as vesting continues.

Insider Trade Summary

68 shares exercised/converted

Mixed 4 txns

Insider Steinhart Richard I

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	35	$0.00	--
Exercise	Common Stock	35	$0.00	--
Exercise	Restricted Stock Units	33	$0.00	--
Exercise	Common Stock	33	$0.00	--

Holdings After Transaction: Restricted Stock Units — 247 shares (Direct); Common Stock — 6,645 shares (Direct)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Form 4 Insider Transactions: What Each Field Means →

03/16/2026 - 08:04 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Steinhart Richard I

(Last)

(First)

(Middle)

C/O BIOXCEL THERAPEUTICS, INC.

555 LONG WHARF DRIVE, 12TH FLOOR

(Street)

NEW HAVEN

06511

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BioXcel Therapeutics, Inc. [ BTAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/14/2026		M		33	A	⁽¹⁾	6,610	D
Common Stock	03/15/2026		M		35	A	⁽¹⁾	6,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/14/2026		M			33	⁽²⁾	⁽²⁾	Common Stock	33	$0	97	D
Restricted Stock Units	⁽¹⁾	03/15/2026		M			35	⁽³⁾	⁽³⁾	Common Stock	35	$0	247	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

3. On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

	/s/ Richard Steinhart	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BioXcel Therapeutics (BTAI) report for Richard Steinhart?

BioXcel Therapeutics reported that CFO Richard Steinhart exercised Restricted Stock Units on March 14 and 15, 2026, converting them into 68 shares of Common Stock at $0.00 per share. These were routine equity compensation events rather than open-market purchases or sales.

How many BioXcel Therapeutics (BTAI) shares does the CFO hold after this Form 4?

After the reported transactions, CFO Richard Steinhart directly holds 6,645 shares of BioXcel Therapeutics Common Stock. This reflects the addition of 68 shares received from exercising Restricted Stock Units, as disclosed in the Form 4 insider filing for March 2026.

What type of securities did BioXcel Therapeutics (BTAI) CFO exercise in this Form 4?

The CFO exercised Restricted Stock Units, which are contingent rights to receive one share of BioXcel Therapeutics Common Stock per unit. On March 14 and 15, 2026, 68 RSUs vested and were converted into 68 shares at an exercise price of $0.00 per share.

Are the BioXcel Therapeutics (BTAI) insider transactions open-market buys or sales?

The transactions are not open-market buys or sales. They are coded as “M,” indicating exercises or conversions of derivative securities (Restricted Stock Units) into Common Stock at $0.00 per share, representing routine equity compensation vesting rather than discretionary trading.

What RSU grants to the BioXcel Therapeutics (BTAI) CFO are referenced in the Form 4 footnotes?

Footnotes describe RSU grants of 521 units on March 14, 2022, and 562 units on March 15, 2023. Each grant vests 25% after one year, then 6.25% every three months, contingent on the CFO’s continuous employment with BioXcel Therapeutics through each vesting date.

How many Restricted Stock Units remain for the BioXcel Therapeutics (BTAI) CFO after these exercises?

After exercising 35 and 33 RSUs on March 15 and March 14, 2026, the CFO has 247 RSUs remaining from the March 15, 2023 grant and 97 RSUs remaining from the March 14, 2022 grant. Each remaining RSU represents a right to one future Common Share.